The TRAVERSE study: redefining what we knew about the safety profile of testosterone replacement therapy

For decades, testosterone replacement therapy (TRT) has been both welcomed and scrutinized, leading to uncertainty around its benefit/risk balance.^1,2

The TRAVERSE study serves as a pivotal step in providing comprehensive safety data on TRT, especially on testosterone gel, the application form used in this study.^1,2

In this study summary you will find out more about the TRAVERSE study and its different sub-studies and learn why it is a game-changer in TRT.^1-7

References: 

1. Bhasin S, et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 Mar;245:41-50.

2. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 Jul 13;389(2):107-117.

3. Pencina KM, et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 Jan 18;109(2):569-580.

4. Bhasin S, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 Dec 1;6(12):e2348692.

5. Pencina KM, et al. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 Oct 2;6(10):e2340030.

6. Bhasin S, et al. Depressive syndromes in men with hypogonadism in the TRAVERSE trial: Response to testosterone-replacement therapy. J Clin Endocrinol Metab. 2024;109(7):1814-1826.

7. Bhasin S, et al. Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial. JAMA Intern Med. 2024;184(4):353-362.